A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
研究单位：[1]Tianjin Medical University Cancer Institute and Hospital[2]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[3]Henan Provincial People''s Hospital,Zhengzhou,Henan,China[4]Hubei Cancer Hospital,Wuhan,Hubei,China[5]The Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China[6]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China[7]the First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shaanxi,China[8]Shandong Cancer Hospital & Institute,Jinan,Shandong,China[9]Sichuan Cancer Hospital,Chengdu,Sichuan,China[10]Sichuan Provincial People''s Hospital,Chengdu,Sichuan,China[11]Ningbo No.2 Hospital,Ningbo,Zhejiang,China[12]Tianjin Medical University Cancer Institute and Hospital,Tianjin,China
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)
